Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Adherium Ltd. ( (AU:ADR) ).
Adherium has reported a change in the interests of director Bruce McHarrie, who holds his stake indirectly through Anticus Pty Ltd as trustee of The Anticus Super Fund. The notice details adjustments to his holding in fully paid ordinary shares of the company, reflecting participation in a recent capital raising.
McHarrie acquired 246,880 new shares at $0.003 each under Adherium’s accelerated non-renounceable entitlement offer to retail investors, lifting his total holding to 617,200 shares. The updated position underscores director support for the company’s funding initiative, with no options exercised and no trades conducted during a closed period.
The most recent analyst rating on (AU:ADR) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Adherium Ltd. stock, see the AU:ADR Stock Forecast page.
More about Adherium Ltd.
Adherium Limited is a healthcare technology company focused on digital respiratory medicine. It develops and supplies connected inhaler devices and related monitoring solutions that support patients and clinicians in managing chronic respiratory conditions, with its securities listed and traded on the ASX.
Technical Sentiment Signal: Sell
Current Market Cap: A$13.03M
For detailed information about ADR stock, go to TipRanks’ Stock Analysis page.